BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man?s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
This report aims to provide a comprehensive presentation of the global market for Oral Drugs for Benign Prostatic Hyperplasia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Drugs for Benign Prostatic Hyperplasia. This report contains market size and forecasts of Oral Drugs for Benign Prostatic Hyperplasia in global, including the following market information:
Global Oral Drugs for Benign Prostatic Hyperplasia Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Oral Drugs for Benign Prostatic Hyperplasia companies in 2022 (%)
The global Oral Drugs for Benign Prostatic Hyperplasia market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Alpha Blockers Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Oral Drugs for Benign Prostatic Hyperplasia include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Viatris, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Oral Drugs for Benign Prostatic Hyperplasia manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Type, 2022 (%)
Alpha Blockers
5-alpha Reductase Inhibitors
Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Application, 2022 (%)
Hospitals
Drugstores
Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues share in global market, 2022 (%)
Key companies Oral Drugs for Benign Prostatic Hyperplasia sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Oral Drugs for Benign Prostatic Hyperplasia sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Viatris
Novartis
Merck
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oral Drugs for Benign Prostatic Hyperplasia, market overview.
Chapter 2: Global Oral Drugs for Benign Prostatic Hyperplasia market size in revenue and volume.
Chapter 3: Detailed analysis of Oral Drugs for Benign Prostatic Hyperplasia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oral Drugs for Benign Prostatic Hyperplasia in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Oral Drugs for Benign Prostatic Hyperplasia capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Oral Drugs for Benign Prostatic Hyperplasia Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oral Drugs for Benign Prostatic Hyperplasia Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oral Drugs for Benign Prostatic Hyperplasia Overall Market Size
2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size: 2022 VS 2029
2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sales: 2018-2029
3 Company Landscape
3.1 Top Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.2 Top Global Oral Drugs for Benign Prostatic Hyperplasia Companies Ranked by Revenue
3.3 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Companies
3.4 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Companies
3.5 Global Oral Drugs for Benign Prostatic Hyperplasia Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Oral Drugs for Benign Prostatic Hyperplasia Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Product Type
3.8 Tier 1, Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.8.1 List of Global Tier 1 Oral Drugs for Benign Prostatic Hyperplasia Companies
3.8.2 List of Global Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size Markets, 2022 & 2029
4.1.2 Alpha Blockers
4.1.3 5-alpha Reductase Inhibitors
4.1.4 Others
4.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
4.2.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2023
4.2.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2024-2029
4.2.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
4.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
4.3.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2023
4.3.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2024-2029
4.3.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
4.4 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Drugstores
5.1.4 Others
5.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
5.2.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2023
5.2.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2024-2029
5.2.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
5.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
5.3.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2023
5.3.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2024-2029
5.3.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
5.4 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2022 & 2029
6.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
6.2.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2023
6.2.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2024-2029
6.2.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
6.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
6.3.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2023
6.3.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2024-2029
6.3.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.4.2 By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.4.3 US Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.4.4 Canada Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.4.5 Mexico Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.5.2 By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.5.3 Germany Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.4 France Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.5 U.K. Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.6 Italy Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.7 Russia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.8 Nordic Countries Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.9 Benelux Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.6.2 By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.6.3 China Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6.4 Japan Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6.5 South Korea Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6.6 Southeast Asia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6.7 India Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.7.2 By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.7.3 Brazil Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.7.4 Argentina Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.8.3 Turkey Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.8.4 Israel Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.8.5 Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.8.6 UAE Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Company Summary
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.1.4 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.1.5 Eli Lilly Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.2.4 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Astellas Pharma
7.3.1 Astellas Pharma Company Summary
7.3.2 Astellas Pharma Business Overview
7.3.3 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.3.4 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.3.5 Astellas Pharma Key News & Latest Developments
7.4 Sanofi
7.4.1 Sanofi Company Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.4.4 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.4.5 Sanofi Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.5.4 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Abbott
7.6.1 Abbott Company Summary
7.6.2 Abbott Business Overview
7.6.3 Abbott Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.6.4 Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.6.5 Abbott Key News & Latest Developments
7.7 Allergan
7.7.1 Allergan Company Summary
7.7.2 Allergan Business Overview
7.7.3 Allergan Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.7.4 Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.7.5 Allergan Key News & Latest Developments
7.8 TEVA
7.8.1 TEVA Company Summary
7.8.2 TEVA Business Overview
7.8.3 TEVA Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.8.4 TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.8.5 TEVA Key News & Latest Developments
7.9 Viatris
7.9.1 Viatris Company Summary
7.9.2 Viatris Business Overview
7.9.3 Viatris Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.9.4 Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.9.5 Viatris Key News & Latest Developments
7.10 Novartis
7.10.1 Novartis Company Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.10.4 Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.10.5 Novartis Key News & Latest Developments
7.11 Merck
7.11.1 Merck Company Summary
7.11.2 Merck Oral Drugs for Benign Prostatic Hyperplasia Business Overview
7.11.3 Merck Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.11.4 Merck Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.11.5 Merck Key News & Latest Developments
8 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, Analysis
8.1 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, 2018-2029
8.2 Oral Drugs for Benign Prostatic Hyperplasia Production Capacity of Key Manufacturers in Global Market
8.3 Global Oral Drugs for Benign Prostatic Hyperplasia Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Oral Drugs for Benign Prostatic Hyperplasia Supply Chain Analysis
10.1 Oral Drugs for Benign Prostatic Hyperplasia Industry Value Chain
10.2 Oral Drugs for Benign Prostatic Hyperplasia Upstream Market
10.3 Oral Drugs for Benign Prostatic Hyperplasia Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Oral Drugs for Benign Prostatic Hyperplasia Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Oral Drugs for Benign Prostatic Hyperplasia in Global Market
Table 2. Top Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Share by Companies, 2018-2023
Table 5. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Companies, (K Units), 2018-2023
Table 6. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Product Type
Table 9. List of Global Tier 1 Oral Drugs for Benign Prostatic Hyperplasia Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2018-2023
Table 15. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2024-2029
Table 16. By Application ? Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2018-2023
Table 20. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2024-2029
Table 21. By Region ? Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2018-2023
Table 25. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), 2024-2029
Table 26. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 29. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2024-2029
Table 30. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 33. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2024-2029
Table 34. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 37. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2024-2029
Table 38. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 41. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales, (K Units), 2024-2029
Table 46. Eli Lilly Company Summary
Table 47. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 48. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Eli Lilly Key News & Latest Developments
Table 50. GlaxoSmithKline Company Summary
Table 51. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 52. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. GlaxoSmithKline Key News & Latest Developments
Table 54. Astellas Pharma Company Summary
Table 55. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 56. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Astellas Pharma Key News & Latest Developments
Table 58. Sanofi Company Summary
Table 59. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 60. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Sanofi Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 64. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Pfizer Key News & Latest Developments
Table 66. Abbott Company Summary
Table 67. Abbott Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 68. Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Abbott Key News & Latest Developments
Table 70. Allergan Company Summary
Table 71. Allergan Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 72. Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Allergan Key News & Latest Developments
Table 74. TEVA Company Summary
Table 75. TEVA Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 76. TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. TEVA Key News & Latest Developments
Table 78. Viatris Company Summary
Table 79. Viatris Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 80. Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Viatris Key News & Latest Developments
Table 82. Novartis Company Summary
Table 83. Novartis Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 84. Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Novartis Key News & Latest Developments
Table 86. Merck Company Summary
Table 87. Merck Oral Drugs for Benign Prostatic Hyperplasia Product Offerings
Table 88. Merck Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Merck Key News & Latest Developments
Table 90. Oral Drugs for Benign Prostatic Hyperplasia Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 91. Global Oral Drugs for Benign Prostatic Hyperplasia Capacity Market Share of Key Manufacturers, 2021-2023
Table 92. Global Oral Drugs for Benign Prostatic Hyperplasia Production by Region, 2018-2023 (K Units)
Table 93. Global Oral Drugs for Benign Prostatic Hyperplasia Production by Region, 2024-2029 (K Units)
Table 94. Oral Drugs for Benign Prostatic Hyperplasia Market Opportunities & Trends in Global Market
Table 95. Oral Drugs for Benign Prostatic Hyperplasia Market Drivers in Global Market
Table 96. Oral Drugs for Benign Prostatic Hyperplasia Market Restraints in Global Market
Table 97. Oral Drugs for Benign Prostatic Hyperplasia Raw Materials
Table 98. Oral Drugs for Benign Prostatic Hyperplasia Raw Materials Suppliers in Global Market
Table 99. Typical Oral Drugs for Benign Prostatic Hyperplasia Downstream
Table 100. Oral Drugs for Benign Prostatic Hyperplasia Downstream Clients in Global Market
Table 101. Oral Drugs for Benign Prostatic Hyperplasia Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Oral Drugs for Benign Prostatic Hyperplasia Segment by Type in 2022
Figure 2. Oral Drugs for Benign Prostatic Hyperplasia Segment by Application in 2022
Figure 3. Global Oral Drugs for Benign Prostatic Hyperplasia Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Oral Drugs for Benign Prostatic Hyperplasia Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029 (US$, Mn)
Figure 7. Oral Drugs for Benign Prostatic Hyperplasia Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Oral Drugs for Benign Prostatic Hyperplasia Revenue in 2022
Figure 9. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
Figure 11. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
Figure 12. By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
Figure 15. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
Figure 16. By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
Figure 20. By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
Figure 21. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
Figure 22. By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
Figure 23. US Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
Figure 28. Germany Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 29. France Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
Figure 37. China Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 41. India Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
Figure 43. By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
Figure 44. Brazil Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
Figure 48. Turkey Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$, Mn), 2018-2029
Figure 52. Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Oral Drugs for Benign Prostatic Hyperplasia by Region, 2022 VS 2029
Figure 54. Oral Drugs for Benign Prostatic Hyperplasia Industry Value Chain
Figure 55. Marketing Channels
